title: Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens.
abstract: BACKGROUND
  Few data are available on the efficacy of second-line H. pylori eradication regimens.
  
  
  OBJECTIVE
  To compare the efficacy of either omeprazole or ranitidine in a second-line quadruple regimen in patients with duodenal ulcer or erosive duodenitis.
  
  
  METHODS
  A total of 37 patients with erosive duodenitis and 119 with duodenal ulcer who have failed eradication of H. pylori with double or triple regimens, without metronidazole, were randomly assigned to receive tripotassium dicitrato bismuthate 600 mg t.d.s. + metronidazole 500 mg t.d.s. + tetracycline hydrochloride 500 mg t.d. s. combined with either omeprazole 20 mg b.d. (group O, 78 patients) or ranitidine 300 mg b.d. (group R, 78 patients) for 14 days. H. pylori eradication was verified by histology, rapid urease test and 13C-urea breath test.
  
  
  METHODS
  t-test, chi2-test.
  
  
  RESULTS
  A total of 143 patients had a post-treatment endoscopy. Eradication rates were: intention-to-treat: group O 77% (67-87), group R 76% (66-85), P=0.85; per protocol analysis: group O 86% (77-95), group R 82 (71-93), P=0.58. Side-effects were frequent but mild.
  
  
  CONCLUSIONS
  Omeprazole 20 mg b.d. and ranitidine 300 mg b.d. were equally effective as antisecretory agents combined in a second-line quadruple eradication regimen.
authors.affiliation: Gastroenterology Unit, Alexandra University Hospital, Athens, Greece. michosp@hol.gr
authors.forename: S
authors.initials: S
authors.lastname: Michopoulos
authors.forename: P
authors.initials: P
authors.lastname: Tsibouris
authors.forename: H
authors.initials: H
authors.lastname: Bouzakis
authors.forename: A
authors.initials: A
authors.lastname: Balta
authors.forename: J
authors.initials: J
authors.lastname: Vougadiotis
authors.forename: N
authors.initials: N
authors.lastname: Broutet
authors.forename: N
authors.initials: N
authors.lastname: Kralios
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000209:etiology; D004382:Duodenitis / Q000209:etiology; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D009942:Organometallic Compounds / Q000008:administration & dosage; D011899:Ranitidine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013752:Tetracycline / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D008795:Metronidazole; D011899:Ranitidine; D013752:Tetracycline; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole